Moderna says Omicron-targeted COVID shot shows better response

Go back to Moderna says Omicron-targeted COVID shot shows better response

Argus Reiterates Buy Rating on Moderna (MRNA), 'Discounted price offers buying opportunity'

June 9, 2022 11:09 AM EDT

Argus analyst John Eade reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).

The analyst comments "We are maintaining our BUY rating on Focus List selection Moderna Inc. (NYSE: MRNA). The company develops therapeutics and... More

Moderna (MRNA) Trades at Low, Down 6.3%

June 9, 2022 10:54 AM EDT

Moderna (NASDAQ: MRNA) Trades at Low, Down 6.3%

... More

Moderna (MRNA) Climbs 4%

June 8, 2022 9:38 AM EDT

Moderna (NASDAQ: MRNA) Climbs 4%

... More